Articles from Kimia Therapeutics, Inc.

Kimia Therapeutics, Inc. (Kimia), a biotechnology company advancing small-molecule medicines in oncology and immunology with its integrated ATLAS discovery platform, today announced a clinical collaboration agreement with CStone Pharmaceuticals (CStone, HKEX: 2616). Under the agreement, CStone will advance Kimia’s lead oncology asset, KT-721, a novel small-molecule therapy targeting pathways critical for tumor cell survival, into Phase 1 clinical development. The collaboration marks Kimia’s transition to a clinical-stage company, with first patient dosing expected in early 2027.